Risk factors for early severe preeclampsia in obstetric antiphospholipid syndrome with conventional treatment. The impact of hydroxychloroquine
Objective The first aim was to retrospectively identify risk factors for the development of early severe preeclampsia (sPE) in patients with obstetric antiphospholipid syndrome (OAPS) who received conventional treatment (CT). The second aim was to evaluate the impact of hydroxychloroquine (HCQ) in p...
Gespeichert in:
| Veröffentlicht in: | Lupus 2020-11, Vol.29 (13), p.1736-1742 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1742 |
|---|---|
| container_issue | 13 |
| container_start_page | 1736 |
| container_title | Lupus |
| container_volume | 29 |
| creator | Latino, José Omar Udry, Sebastián Aranda, Federico Wingeyer, Silvia Perés Romero, Diego Santiago Fernández Belizna, Cristina Larrañaga, Gabriela de |
| description | Objective
The first aim was to retrospectively identify risk factors for the development of early severe preeclampsia (sPE) in patients with obstetric antiphospholipid syndrome (OAPS) who received conventional treatment (CT). The second aim was to evaluate the impact of hydroxychloroquine (HCQ) in preventing early sPE among a subgroup of patients considered at high risk.
Methods
A total of 102 women diagnosed with OAPS and treated with CT since the diagnosis of pregnancy were selected. At the end of pregnancy, we identified risk factors associated with early sPE. According to these risk factors, we collected a new cohort of 42 patients who presented high-risk factors for developing early sPE and split them into two groups according to the treatment received: group A, CT (30 patients); and group B, CT+HCQ (12 patients). We evaluated and compared pregnancy outcomes in both groups.
Results
According to the multivariate analysis, risk factors associated with early sPE and CT were triple positivity for antiphospholipid antibodies (aPL) (OR = 24.70, [4.27–142.92], p |
| doi_str_mv | 10.1177/0961203320952850 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2437127513</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0961203320952850</sage_id><sourcerecordid>2457236336</sourcerecordid><originalsourceid>FETCH-LOGICAL-c342t-e1e6b9a6072762a0263f733cce48b63d9ce27e32ce1037a075adb702f40208683</originalsourceid><addsrcrecordid>eNp1kd9LxDAMx4soeJ6--1jwxZdp2m7t7VHEX3AgiD6PXi9z1W2dbU_dX-G_bMcJgiAkhCSfb0IIIccMzhhT6hxKyTgIwaEs-KKAHTJjuVJZqvNdMpva2dTfJwchvACAYKWcka8HG15prU10PtDaeYratyMN-I4e6eARTau7IVhNbU_dKkSM3hqq-2iHxoXkrR3smoaxX3vXIf2wsaHG9e-YENfrlkaPOnYpPaOPDVLbDWkfdTVtxiT5HE3TOu_eNrbHQ7JX6zbg0U-ck6frq8fL22x5f3N3ebHMjMh5zJChXJVaguJKcg1ciloJYQzmi5UU69IgVyi4QQZCaVCFXq8U8DoHDgu5EHNyup07TIsxxKqzwWDb6h7dJlQ8F4pxVTCR0JM_6Ivb-HTXRBWKCymSzQlsKeNdCB7ravC2036sGFTTh6q_H0qSbCsJ-hl_h_7LfwMzDpLr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2457236336</pqid></control><display><type>article</type><title>Risk factors for early severe preeclampsia in obstetric antiphospholipid syndrome with conventional treatment. The impact of hydroxychloroquine</title><source>SAGE Complete A-Z List</source><creator>Latino, José Omar ; Udry, Sebastián ; Aranda, Federico ; Wingeyer, Silvia Perés ; Romero, Diego Santiago Fernández ; Belizna, Cristina ; Larrañaga, Gabriela de</creator><creatorcontrib>Latino, José Omar ; Udry, Sebastián ; Aranda, Federico ; Wingeyer, Silvia Perés ; Romero, Diego Santiago Fernández ; Belizna, Cristina ; Larrañaga, Gabriela de</creatorcontrib><description>Objective
The first aim was to retrospectively identify risk factors for the development of early severe preeclampsia (sPE) in patients with obstetric antiphospholipid syndrome (OAPS) who received conventional treatment (CT). The second aim was to evaluate the impact of hydroxychloroquine (HCQ) in preventing early sPE among a subgroup of patients considered at high risk.
Methods
A total of 102 women diagnosed with OAPS and treated with CT since the diagnosis of pregnancy were selected. At the end of pregnancy, we identified risk factors associated with early sPE. According to these risk factors, we collected a new cohort of 42 patients who presented high-risk factors for developing early sPE and split them into two groups according to the treatment received: group A, CT (30 patients); and group B, CT+HCQ (12 patients). We evaluated and compared pregnancy outcomes in both groups.
Results
According to the multivariate analysis, risk factors associated with early sPE and CT were triple positivity for antiphospholipid antibodies (aPL) (OR = 24.70, [4.27–142.92], p < 0.001) and a history of early sPE (OR = 7.11, [1.13–44.64], p = 0.036). A low-risk aPL profile was associated with a good response to CT in preventing early sPE (OR = 0.073, [0.014–0.382], p = 0.002). High-risk patients treated with CT+HCQ had a significantly lower early sPE rate than those treated with CT only (8.3% vs 40.0%; p = 0.03).
Conclusion
Triple positivity for aPL and a history of early sPE are potential strong risk factors for the development of early sPE. HCQ might be an interesting therapeutic option for patients with high-risk factors for early sPE.</description><identifier>ISSN: 0961-2033</identifier><identifier>EISSN: 1477-0962</identifier><identifier>DOI: 10.1177/0961203320952850</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Anticoagulants ; Antiphospholipid antibodies ; Antiphospholipid syndrome ; Autoimmune diseases ; Hydroxychloroquine ; Multivariate analysis ; Obstetrics ; Pre-eclampsia ; Preeclampsia ; Pregnancy ; Risk factors ; Risk groups</subject><ispartof>Lupus, 2020-11, Vol.29 (13), p.1736-1742</ispartof><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c342t-e1e6b9a6072762a0263f733cce48b63d9ce27e32ce1037a075adb702f40208683</citedby><cites>FETCH-LOGICAL-c342t-e1e6b9a6072762a0263f733cce48b63d9ce27e32ce1037a075adb702f40208683</cites><orcidid>0000-0002-2527-7298</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0961203320952850$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0961203320952850$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21818,27923,27924,43620,43621</link.rule.ids></links><search><creatorcontrib>Latino, José Omar</creatorcontrib><creatorcontrib>Udry, Sebastián</creatorcontrib><creatorcontrib>Aranda, Federico</creatorcontrib><creatorcontrib>Wingeyer, Silvia Perés</creatorcontrib><creatorcontrib>Romero, Diego Santiago Fernández</creatorcontrib><creatorcontrib>Belizna, Cristina</creatorcontrib><creatorcontrib>Larrañaga, Gabriela de</creatorcontrib><title>Risk factors for early severe preeclampsia in obstetric antiphospholipid syndrome with conventional treatment. The impact of hydroxychloroquine</title><title>Lupus</title><description>Objective
The first aim was to retrospectively identify risk factors for the development of early severe preeclampsia (sPE) in patients with obstetric antiphospholipid syndrome (OAPS) who received conventional treatment (CT). The second aim was to evaluate the impact of hydroxychloroquine (HCQ) in preventing early sPE among a subgroup of patients considered at high risk.
Methods
A total of 102 women diagnosed with OAPS and treated with CT since the diagnosis of pregnancy were selected. At the end of pregnancy, we identified risk factors associated with early sPE. According to these risk factors, we collected a new cohort of 42 patients who presented high-risk factors for developing early sPE and split them into two groups according to the treatment received: group A, CT (30 patients); and group B, CT+HCQ (12 patients). We evaluated and compared pregnancy outcomes in both groups.
Results
According to the multivariate analysis, risk factors associated with early sPE and CT were triple positivity for antiphospholipid antibodies (aPL) (OR = 24.70, [4.27–142.92], p < 0.001) and a history of early sPE (OR = 7.11, [1.13–44.64], p = 0.036). A low-risk aPL profile was associated with a good response to CT in preventing early sPE (OR = 0.073, [0.014–0.382], p = 0.002). High-risk patients treated with CT+HCQ had a significantly lower early sPE rate than those treated with CT only (8.3% vs 40.0%; p = 0.03).
Conclusion
Triple positivity for aPL and a history of early sPE are potential strong risk factors for the development of early sPE. HCQ might be an interesting therapeutic option for patients with high-risk factors for early sPE.</description><subject>Anticoagulants</subject><subject>Antiphospholipid antibodies</subject><subject>Antiphospholipid syndrome</subject><subject>Autoimmune diseases</subject><subject>Hydroxychloroquine</subject><subject>Multivariate analysis</subject><subject>Obstetrics</subject><subject>Pre-eclampsia</subject><subject>Preeclampsia</subject><subject>Pregnancy</subject><subject>Risk factors</subject><subject>Risk groups</subject><issn>0961-2033</issn><issn>1477-0962</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kd9LxDAMx4soeJ6--1jwxZdp2m7t7VHEX3AgiD6PXi9z1W2dbU_dX-G_bMcJgiAkhCSfb0IIIccMzhhT6hxKyTgIwaEs-KKAHTJjuVJZqvNdMpva2dTfJwchvACAYKWcka8HG15prU10PtDaeYratyMN-I4e6eARTau7IVhNbU_dKkSM3hqq-2iHxoXkrR3smoaxX3vXIf2wsaHG9e-YENfrlkaPOnYpPaOPDVLbDWkfdTVtxiT5HE3TOu_eNrbHQ7JX6zbg0U-ck6frq8fL22x5f3N3ebHMjMh5zJChXJVaguJKcg1ciloJYQzmi5UU69IgVyi4QQZCaVCFXq8U8DoHDgu5EHNyup07TIsxxKqzwWDb6h7dJlQ8F4pxVTCR0JM_6Ivb-HTXRBWKCymSzQlsKeNdCB7ravC2036sGFTTh6q_H0qSbCsJ-hl_h_7LfwMzDpLr</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Latino, José Omar</creator><creator>Udry, Sebastián</creator><creator>Aranda, Federico</creator><creator>Wingeyer, Silvia Perés</creator><creator>Romero, Diego Santiago Fernández</creator><creator>Belizna, Cristina</creator><creator>Larrañaga, Gabriela de</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2527-7298</orcidid></search><sort><creationdate>202011</creationdate><title>Risk factors for early severe preeclampsia in obstetric antiphospholipid syndrome with conventional treatment. The impact of hydroxychloroquine</title><author>Latino, José Omar ; Udry, Sebastián ; Aranda, Federico ; Wingeyer, Silvia Perés ; Romero, Diego Santiago Fernández ; Belizna, Cristina ; Larrañaga, Gabriela de</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c342t-e1e6b9a6072762a0263f733cce48b63d9ce27e32ce1037a075adb702f40208683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Anticoagulants</topic><topic>Antiphospholipid antibodies</topic><topic>Antiphospholipid syndrome</topic><topic>Autoimmune diseases</topic><topic>Hydroxychloroquine</topic><topic>Multivariate analysis</topic><topic>Obstetrics</topic><topic>Pre-eclampsia</topic><topic>Preeclampsia</topic><topic>Pregnancy</topic><topic>Risk factors</topic><topic>Risk groups</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Latino, José Omar</creatorcontrib><creatorcontrib>Udry, Sebastián</creatorcontrib><creatorcontrib>Aranda, Federico</creatorcontrib><creatorcontrib>Wingeyer, Silvia Perés</creatorcontrib><creatorcontrib>Romero, Diego Santiago Fernández</creatorcontrib><creatorcontrib>Belizna, Cristina</creatorcontrib><creatorcontrib>Larrañaga, Gabriela de</creatorcontrib><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Lupus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Latino, José Omar</au><au>Udry, Sebastián</au><au>Aranda, Federico</au><au>Wingeyer, Silvia Perés</au><au>Romero, Diego Santiago Fernández</au><au>Belizna, Cristina</au><au>Larrañaga, Gabriela de</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk factors for early severe preeclampsia in obstetric antiphospholipid syndrome with conventional treatment. The impact of hydroxychloroquine</atitle><jtitle>Lupus</jtitle><date>2020-11</date><risdate>2020</risdate><volume>29</volume><issue>13</issue><spage>1736</spage><epage>1742</epage><pages>1736-1742</pages><issn>0961-2033</issn><eissn>1477-0962</eissn><abstract>Objective
The first aim was to retrospectively identify risk factors for the development of early severe preeclampsia (sPE) in patients with obstetric antiphospholipid syndrome (OAPS) who received conventional treatment (CT). The second aim was to evaluate the impact of hydroxychloroquine (HCQ) in preventing early sPE among a subgroup of patients considered at high risk.
Methods
A total of 102 women diagnosed with OAPS and treated with CT since the diagnosis of pregnancy were selected. At the end of pregnancy, we identified risk factors associated with early sPE. According to these risk factors, we collected a new cohort of 42 patients who presented high-risk factors for developing early sPE and split them into two groups according to the treatment received: group A, CT (30 patients); and group B, CT+HCQ (12 patients). We evaluated and compared pregnancy outcomes in both groups.
Results
According to the multivariate analysis, risk factors associated with early sPE and CT were triple positivity for antiphospholipid antibodies (aPL) (OR = 24.70, [4.27–142.92], p < 0.001) and a history of early sPE (OR = 7.11, [1.13–44.64], p = 0.036). A low-risk aPL profile was associated with a good response to CT in preventing early sPE (OR = 0.073, [0.014–0.382], p = 0.002). High-risk patients treated with CT+HCQ had a significantly lower early sPE rate than those treated with CT only (8.3% vs 40.0%; p = 0.03).
Conclusion
Triple positivity for aPL and a history of early sPE are potential strong risk factors for the development of early sPE. HCQ might be an interesting therapeutic option for patients with high-risk factors for early sPE.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><doi>10.1177/0961203320952850</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-2527-7298</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0961-2033 |
| ispartof | Lupus, 2020-11, Vol.29 (13), p.1736-1742 |
| issn | 0961-2033 1477-0962 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2437127513 |
| source | SAGE Complete A-Z List |
| subjects | Anticoagulants Antiphospholipid antibodies Antiphospholipid syndrome Autoimmune diseases Hydroxychloroquine Multivariate analysis Obstetrics Pre-eclampsia Preeclampsia Pregnancy Risk factors Risk groups |
| title | Risk factors for early severe preeclampsia in obstetric antiphospholipid syndrome with conventional treatment. The impact of hydroxychloroquine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T07%3A21%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20factors%20for%20early%20severe%20preeclampsia%20in%20obstetric%20antiphospholipid%20syndrome%20with%20conventional%20treatment.%20The%20impact%20of%20hydroxychloroquine&rft.jtitle=Lupus&rft.au=Latino,%20Jos%C3%A9%20Omar&rft.date=2020-11&rft.volume=29&rft.issue=13&rft.spage=1736&rft.epage=1742&rft.pages=1736-1742&rft.issn=0961-2033&rft.eissn=1477-0962&rft_id=info:doi/10.1177/0961203320952850&rft_dat=%3Cproquest_cross%3E2457236336%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2457236336&rft_id=info:pmid/&rft_sage_id=10.1177_0961203320952850&rfr_iscdi=true |